Although anti-B7 monoclonal antibodies alone do not promote alloengraftment, they enhance engraftment promotion by anti-CD154 monoclonal antibody
| TBI (cGy) . | mAb . | No. chimeric . | % Donor . |
|---|---|---|---|
| 100 | Hamster IgG | 0/10 | 0 ± 0 |
| 100 | Anti-CD154* | 7/9 | 32 ± 20‡ |
| 100 | Anti-CD80, anti-CD86* | 0/10 | 0 ± 0 |
| 100 | Anti-CD154, anti-CD80, anti-CD86* | 10/10 | 51 ± 4‡,2-153 |
| 100 | Anti-CD154† | 7/10 | 20 ± 16‡ |
| 100 | Anti-CD154, anti-CD80, anti-CD86† | 10/10 | 51 ± 5‡,2-153 |
| TBI (cGy) . | mAb . | No. chimeric . | % Donor . |
|---|---|---|---|
| 100 | Hamster IgG | 0/10 | 0 ± 0 |
| 100 | Anti-CD154* | 7/9 | 32 ± 20‡ |
| 100 | Anti-CD80, anti-CD86* | 0/10 | 0 ± 0 |
| 100 | Anti-CD154, anti-CD80, anti-CD86* | 10/10 | 51 ± 4‡,2-153 |
| 100 | Anti-CD154† | 7/10 | 20 ± 16‡ |
| 100 | Anti-CD154, anti-CD80, anti-CD86† | 10/10 | 51 ± 5‡,2-153 |
B6 mice were irradiated with 100 cGy TBI on day −1 and infused with 40 × 106 BALB/c BM on day 0.
For abbreviations, see Table 1.
Antibodies were administered from day −1 through day 14.
A second schedule of antibodies was examined whereby antibodies were administered only on days −1, 0, and 1 after BMT. PBLs were typed for percentage donor-host chimerism on 120 day after BMT. Chimeric is defined as more than 3% donor PBLs. Percentage donor is average percentage donor cells of all mice in the group ± 1 SD.
P < .001 compared to hamster IgG.
P = .01 compared to anti-CD154 alone.P = .176 for anti-CD154 administered for 2 weeks after BMT versus days −1, 0, and 1.